Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT04329234
Recruiting Observational

Korean Heart Failure Registry III

NCT04329234 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Bundang Hospital
Phase
Observational
Started
2018-10-01
Last updated
2020-04-01

Condition(s) studied

Acute Heart Failure

Study summary

KorHF III is a multi-center, nationwide, prospective registry of the Korean Society of Heart Failure, which enrolls patients with acute heart failure in Korea.

The aim of this registry is to analyze the etiology, treatment, treatment, and prognosis to develop strategies for managing acute heart failure.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
All consecutive hospitalized adult heart failure patients who fulfill one of 1-3 and 4 Inclusion Criteria: 1. Symptoms of heart failure 2. Signs of heart failure 3. Lung congestion in Chest-x-ray 4. Objective finding of structural and/or functional disorder of the heart or elevated natriuretic peptide levels Exclusion Criteria: 1. Patients younger than 18 years old 2. Patients who do no consent

Primary outcome measure(s)

  • In-hospital mortality — 5 years
    In-hospital mortality
  • Post-discharge mortality — 5 years
    Post-discharge mortality
  • Post-discharge re-hospitalization — 5 years
    Post-discharge re-hospitalization

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Bundang Hospital Seongnam South Korea Recruiting

More Seoul National University Bundang Hospital trials in South Korea

Pepsinogen II and Helicobacter Pylori Test in Gastric Cancer Active, not recruiting
A Study on the Effects of A2 Milk on Gut Beneficial Bacteria Growth and Digestion Improvement Active, not recruiting
Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism Recruiting
Dual-chamber Patient-controlled Analgesia for Postoperative Recovery Recruiting
Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes Recruiting

Other trials for the same condition

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04329234 on ClinicalTrials.gov ↗ ← All trials in South Korea